Determination of mesalamine related impurities from drug product by reversed phase validated UPLC method

E-Journal of Chemistry

Volumn 8, Issue 1, 2011, Pages 131-148

  Trivedi, Rakshit Kanubhai ^a   Patel, Mukesh C ^b   Kharkar, Amit R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

^b PS Science and HDPatel Arts College   (India)

Author keywords

5 aminosalicylic acid; Mesalamine; Stability indicating; UPLC; Validation

Indexed keywords

EID: 79951587222     PISSN: None     EISSN: 09734945     Source Type: Journal    
DOI: 10.1155/2011/382137     Document Type: Article

References (42)

1. Gisbert J P, Gomollon F, Mate J and Pajares J M, A systematic review., Dig Dis Sci 2002, 47, 471-488.
2. Klotz U, Maier K, Fisher C and Heinkel K, Eur J Clin Pharmacol., 2000, 56, 353-362.
3. De Vos M, Clin Pharmacokinet., 2000, 39, 85-97.
4. http://en.wikipedia.org/wiki/Mesalazine
5. Pappercorn M A and Goldman P, Gastroenterology, 1973, 64(2), 240-245.
6. Haagen Nielsen O and Bondesen S, Br J Clin Pharmacol., 1983, 16(6), 738-740.
7. Schröder H and Compbell D E, Clin Pharmacol Ther, 1972, 13(4), 539-551.
8. th Ed., Pergamon, 1990, p 650.
9. Reynolds J F, (Ed.) Martindale. The Extra Pharmacopoeia, Royal Pharmaceutical Society, London, 1996, p.1227.
10. Alekha K Dash and Harry G Brittain, Analytical Profile of Drug Substances and Excipients, 1998, 25, 209-242; doi: 10.1016/S0099-5428(08).
11. Rita K Palsmeier, Donna M Radzik and Craig E Lunte, Pharma Res., 1992, 9(7), 933-938.
12. Zhou S Y, Fleisher D, Pao L H, Li C, Winward B, Zimmermann E M, Drug Metab Dispos., 1999, 27(4), 479-485.
13. Liu Z C, McClelland R A and Uetrecht J P, Drug Metab Dispos., 1995, 23(2), 246-250.
14. Bystrowska B, Nowak J and Brandys J, J Pharma Biomed Anal., 2000, 22(2), 341-347.
15. Fischer C and Klotz U, J Chromatogr. 1979, 162(2), 237-243.
16. Palmbo G, Bucchi S, Primavera L, Palumbo P and Carlucci G, Biomed Chromatogr., 2005, 19(5), 350-354.
17. Elisabetta Paslorini, Marcello Locatelli, Patrizia Simoni, Giulia Roda, Enrico Roda and Aldo Roda, J Chromatogr B Analyt Technol Biomed Life Sci., 2008, 872(1-2), 99-106.
18. Fischer C, Maier K and Klotz U, J Chromatogr., 1981, 225(2), 498-503.
19. Beata Bystrowska, Jolanta Nowak and Jerzy Brandys, J Pharma Biomed Anal., 2000, 22(2), 341-347.
20. Nobilis M, Vybiralova Z, Sladkova K, Lisa M, Holcapek M and J Kvetina, J Chromatogr A, 2006, 1119(1-2), 299-308.
21. Lecompte S, Simard M, Gauthier G and Donato L Di, A sensitive HPLC Method for the Determination of Mesalamine and its Metabolite in human Plasma using Fluorescence Detection., Phoenix International Life Sciences., Montreal, PQ Canada, 2000; www.aapsj.org/abstracts/AM-2000/2596.htm
22. Hussain F N, Ajjan R A, Moustafa M, Anderson J C and Riley S A, J Chromatogr B, 1998, 716(1-2), 257-266.
23. Palumbo G, Carlucci G, Mazzeo P, Frieri G, Pimpo MT, Fanini D, J Pharm Biomed Anal., 1995, 14(1-2), 175-180.
24. Predrag Novak, Predrag Tepes, Ines Fistric, Lgor Bratos and Vesna Gabelica, J Pharma Biomed Anal., 2006, 40(5), 1268-1272.
25. Joan Jensen, Claus Cornett, Carl Erik Olsen, Jette Tjornelund and Steen Honore Hansen, Int J Pharma., 1992, 88(1-3), 177-187.
26. Tang J, Sharif O, Pai C and Silverman A L, Dig Dis Sci. 2010, 55(6), 1696-1703.
27. Brian S. Kersten, Tom Catalano and Yury Rozenman, J Chromatogr A, 1991, 588(1-2), 187-193.
28. Haney P W, Dash A K, J Chromatogr A, 1997, 765(2), 233-239.
29. Arbad B R and Jadhav S M, Asian J Chem., 2000, 12(1), 294-296.
30. Majji Sunil, Srinivasa Rao K and Rao M E B, Analytical Chemistry, An Indian Journal, 2008, 7(7), 546-550.
31. Biljana Nigovi and Branimir Imuni, J Pharma Biomed Anal., 2003, 32(1), 169-174.
32. Lee Allen, Julie Weinberger and Robert Weinberger,.J Chromatogr A, 2004, 1053(1-2), 217-226.
33. Roberto Gotti, Romeo Pomponio, Carlo Bertucci and Vanni Cavrini, J Chromatogr A, 2001, 916(1-2), 175-183.
34. Janice Aparecida Rafael, jose Roberto Jabor, Rubia Casagrande, Sandra Regina Georgetti, Maria de Fatima Borin and Maria Jose Vieira Fonseca, Brazilian J Pharma Sci., 2007, 43(1), 97-103.
35. United States Pharmacopeia, USP32-NF27, p 2895.
36. United States Pharmacopeia, USP32-NF27, p 2897.
37. United States Pharmacopeia, USP32-NF27, p 2894.
38. British Pharmacopoeia, BP- 2010, p 1368.
39. ICH, Validation of Analytical Procedure, Text and Methodology Q2 (R1): International conference on Harmonization, IFPMA, Geneva, 2005.
40. ICH, Stability testing of New drug Substances and Product (Q1AR), International conference on Harmonization, IFPMA, Geneva, 2002.
41. Genotoxic and Carcinogenic Impurities in drug Substances and Products: Recommended approaches. FDA Center for Drug Evaluation and Research. Guidance for Industry (Draft), 3 December 2008.
42. Derek I Robinson, A review and Perspective Organic Process Research and Development, 2010, 14, 946-959.